ライフサイエンスコーパス: portal vein thrombosis

1 ary embolism, 18 deep vein thrombosis, and 2 portal vein thrombosis).

2 ening islet survival and potentially causing portal vein thrombosis.

3 Three (2.9%) grafts were lost due to portal vein thrombosis.

4 source of infection and presenting with left portal vein thrombosis.

5 ing for age, sex, treatment, tumor size, and portal vein thrombosis.

6 a higher change of complications related to portal vein thrombosis.

7 ut was present in 62.5% of the patients with portal vein thrombosis.

8 There was no incidence of hepatic artery or portal vein thrombosis.

9 y independent risk factor for pre-transplant portal vein thrombosis.

10 es because of unexpected acute rejection and portal vein thrombosis.

11 patient required retransplantation, owing to portal vein thrombosis.

12 ies, 8 required surgical shunts for complete portal vein thrombosis.

13 e the relationship between folate status and portal vein thrombosis.

14 hic scan showed superior mesenteric vein and portal vein thrombosis.

15 t entry criteria, and 2 were excluded due to portal vein thrombosis.

16 y subjects were included, and 64 (15.7%) had portal vein thrombosis.

17 of 0.001, were significantly associated with portal vein thrombosis.

18 4), acute chest syndrome (5), pneumonia (2), portal vein thrombosis (1), priapism (1), hemolytic urem

19 his study found a notably high prevalence of portal vein thrombosis (15.7%) among hospitalized patien

20 were mainly rejected for comorbidity (19%), portal vein thrombosis (16%), previous surgery (9%), obe

21 ently in OPV than in cirrhosis: extrahepatic portal vein thrombosis (18 [43%] of 42 vs five [12%] of

22 erved post-COVID-19 vaccination, followed by portal vein thrombosis (52 cases), raised liver enzymes

23 hepatocellular carcinoma (61 [55%]), without portal vein thrombosis (87 [78%]).

24 lenectomy was associated with development of portal vein thrombosis after surgery (P = 0.01).

25 ther evaluations revealed a mild ascites and portal vein thrombosis although the patient received pro

26 dy was conducted to assess the prevalence of portal vein thrombosis and associated factors among pati

27 .4%; 20-year survival, 12.5%). patients with portal vein thrombosis and biliary cirrhosis demonstrate

28 wo (16.3%) patients developed pre-transplant portal vein thrombosis and its presence had no impact in

29 tic thrombosis, and radiologic management of portal vein thrombosis and stenosis has decreased operat

30 Two donors developed portal vein thrombosis, and 1 had inferior vena caval th

31 C, 56% had more than 1 tumor nodule, 24% had portal vein thrombosis, and 29% did not receive any canc

32 ism, disseminated intravascular coagulation, portal vein thrombosis, and arterial thromboembolism.

33 as hepatorenal syndrome, hepatichydrothorax, portal vein thrombosis, and Budd-Chiari syndrome.

34 inib secondary to cerebrovascular ischaemia, portal vein thrombosis, and coronary artery stenosis in

35 analysis Child-Pugh score, presence of HCC, portal vein thrombosis, and lack of secondary prophylaxi

36 e II diabetes mellitus, renal insufficiency, portal vein thrombosis, and poor performance status.

37 ced disease, increased inflammatory changes, portal vein thrombosis, and substantially lower survival

38 iagnosis and management of acute symptomatic portal vein thrombosis are essential.

39 Left sided abscess and portal vein thrombosis are rare and hence reported.

40 as associated with an increased incidence of portal-vein thrombosis, as compared with placebo.

41 Portal vein thrombosis at listing was not associated wit

42 Portal vein thrombosis at LT is associated with early (9

43 growing body of evidence has indicated that portal vein thrombosis, autoimmune hepatitis, raised liv

44 tis/cholecystitis, pancreatitis, hemorrhage, portal vein thrombosis, bowel wall perforation, or dehyd

45 f orthotopic liver transplantation, in which portal vein thrombosis developed in the immediate postop

46 operation (MLPVB) in correcting extrahepatic portal vein thrombosis (EHPVT) in children.

47 s of the liver in children with extrahepatic portal vein thrombosis (EHPVT), with surgical outcome af

48 Budd-Chiari syndrome (BCS) and portal vein thrombosis have been reported to be associat

49 last decade a large number of patients with portal vein thrombosis have undergone successful liver t

50 igher mortality and complications, including portal vein thrombosis, hepatic encephalopathy, and gast

51 We aimed to characterize the pre-transplant portal vein thrombosis in a cohort of liver transplant r

52 ascular stent placement for the treatment of portal vein thrombosis in liver transplant recipients.

53 We speculated that the underlying cause of portal vein thrombosis in our case was coronaviruses.

54 Management of portal vein thrombosis in patients with cirrhosis is mor

55 nt placement were successfully used to treat portal vein thrombosis in patients with recent liver tra

56 Portal vein thrombosis is a frequent complication in end

57 rahepatic portal vein occlusion (EHPVO) from portal vein thrombosis is a rare condition associated wi

58 In patients with cirrhosis, development of portal vein thrombosis is often insidious and remains un

59 Portal vein thrombosis is the most common cause of porta

60 patients with Budd-Chiari syndrome and with portal vein thrombosis, Kiladjian et al observed that JA

61 Portal vein thrombosis, location in intensive care unit,

62 n associated with hepatic artery (n = 15) or portal vein thrombosis (n = 14).Mean surgical time was 1

63 ases for acute hepatic failure (n = 4, 50%), portal vein thrombosis (n = 25, 48.1%), splanchnic vein

64 liver disease (MELD) score <=25, absence of portal vein thrombosis, no mechanical ventilation at the

65 pared with non-BCS liver recipients), one of portal vein thrombosis (nonsignificant [NS]), and one of

66 Segmental left portal vein thrombosis occurred in 1 patient and intralu

67 cephalopathy (odds ratio, 4.4; P = .001) and portal vein thrombosis (odds ratio, 5.3; P = .001) were

68 d with the presence of SPSSs (any size) were portal vein thrombosis (odds ratio, 5.5; P = .008) and C

69 t survival for patients who have experienced portal vein thrombosis or stenosis is 61% and 67%, respe

70 There were no wound infections, portal vein thrombosis, or fluid and electrolyte abnorma

71 ipients due to cardiovascular comorbidities, portal vein thrombosis, or to manage posttransplant comp

72 ardial infarct, perioperative hemorrhage, or portal vein thrombosis--or death occurred as a result of

73 001), MELD score greater than 10 (P = .001), portal vein thrombosis (P = .0001), and tumor diameter g

74 downstaged toward resection, including most portal vein thrombosis patients.

75 nt differences in hepatic artery thrombosis, portal vein thrombosis, primary nonfunction, and biliary

76 s possible even in the presence of recipient portal vein thrombosis, provided that hepatopetal portal

77 The unreported major NCFs were portal vein thrombosis, pulmonary nodule, pulmonary embo

78 logy Group (ECOG), presence of cirrhosis and portal vein thrombosis (PVT) (none, branch, and main).

79 Portal vein thrombosis (PVT) and different cardiovascula

80 patients of liver cirrhosis associated with portal vein thrombosis (PVT) can be effectively treated

81 In cirrhosis, portal vein thrombosis (PVT) could be a cause or a conse

82 Portal vein thrombosis (PVT) has been reported to have a

83 low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced c

84 Portal vein thrombosis (PVT) is a common complication of

85 Portal vein thrombosis (PVT) is a common complication of

86 Portal vein thrombosis (PVT) is a frequent complication

87 Portal vein thrombosis (PVT) is a Liver vascular disease

88 Portal vein thrombosis (PVT) is common in patients with

89 Nonneoplastic portal vein thrombosis (PVT) is frequent in patients wit

90 Portal vein thrombosis (PVT) makes the technical aspect

91 Hepatic artery thrombosis and portal vein thrombosis (PVT) occurred in 9% and 7%, whil

92 Portal vein thrombosis (PVT) occurs frequently in hepato

93 ate and survival of hepatocellular carcinoma portal vein thrombosis (PVT) patients treated with (90)Y

94 Further, portal vein thrombosis (PVT) pre-liver transplant (LT) i

95 Assess anticoagulation practice and portal vein thrombosis (PVT) risk following pancreaticod

96 Patients with Child-Pugh B disease who had portal vein thrombosis (PVT) survived 5.6 months (95% co

97 ed-stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with (90)Y radioemb

98 onths with no significant difference between portal vein thrombosis (PVT) versus no PVT (7 versus 13

99 The 1-year probability of developing portal vein thrombosis (PVT) was 9%, and 53% of patients

100 osal EV on contrast-enhanced CT, presence of portal vein thrombosis (PVT), and patent umbilical vein

101 tients with chronic noncirrhotic, nontumoral portal vein thrombosis (PVT), the usually recommended st

102 ocellular carcinoma (HCC), including 16 with portal vein thrombosis (PVT), were treated with (90)Y-lo

103 leeding from portal hypertension but also by portal vein thrombosis (PVT).

104 yndrome (BCS) and nonmalignant, noncirrhotic portal vein thrombosis (PVT).

105 s occurred in eight patients (75% nontumoral portal vein thrombosis [PVT]).

106 ion (Budd-Chiari Syndrome) and in those with portal vein thrombosis (second section); and we briefly

107 stribution hazard ratio, 2.9; P = .039), and portal vein thrombosis (subdistribution hazard ratio, 7.

108 Venous complications included portal vein thrombosis, transverse and sagittal sinus th

109 atocellular carcinoma (HCC) with and without portal vein thrombosis underwent radioembolization with

110 ease, cytomegalovirus infection and disease, portal vein thrombosis, UNOS status, Childs-Pugh score,

111 Portal vein thrombosis unrelated to solid malignancy is

112 Incidence of postoperative portal vein thrombosis was higher in low flow after repe

113 Portal vein thrombosis was identified in 17 of 21 patien

114 Portal vein thrombosis was independently associated with

115 Portal vein thrombosis was present in 11 patients (6%).

116 e lab data regarding the secondary causes of portal vein thrombosis were normal.

117 60.1 years; range, 32-75 years) with HCC and portal vein thrombosis who were examined with both contr